Study to Evaluate the Relative Abuse Potential of Almorexant in Recreational Drug Users

NCT01987739 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

42

Enrollment

INDUSTRY

Sponsor class

Conditions

Abuse Potential Study

Interventions

DRUG: 200 mg almorexant
DRUG: 400 mg almorexant
DRUG: 1000 mg almorexant
DRUG: 20 mg zolpidem
DRUG: 40 mg zolpidem
DRUG: placebo

Sponsor

Midnight Pharma, LLC